Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation–Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study
Jorge Raul Vazquez-Urrutia, Natasha Venugopal, Junjia Zhu, Takefumi Komiya · 2026
Read Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation–Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study by Jorge Raul Vazquez-Urrutia, Natasha Venugopal, Junjia Zhu, Takefumi Komiya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13171259.txt.
Description
Three gene faults turn up oft in lung tumours that lack a drug dock, and past work ties them to poor odds. Jorge Raul Vazquez-Urrutia and co-authors test that tie in a 2026 study of one hundred and nineteen such patients at one centre. They split the group by fresh ill and by ill come back.
The top fault, in a guard gene, showed in more than half of both groups. The twin faults sat in a tenth or so of each. Life spans and free spans ran much the same what fault a tumour held, in fresh and come back groups alike. The team calls for far larger sets to settle the marks' worth.
Catalog record
| CREATOR | Jorge Raul Vazquez-Urrutia, Natasha Venugopal, Junjia Zhu, Takefumi Komiya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |